TBBi (4,5,6,7-tetrabromobenzimidazole, TBBz) is a potent, selective and ATP-competitive CK2 inhibitor with Ki of 0.5-1 uM.
TBBi weakly inhibits CK1 (about 100-fold less potent), and has no activity for PKA and PKC.
TBBi decreases the activity of GBM-initiating cell regulator β-catenin, reduces cell growth, decreases tumor size, and increases survival rates in GBM xenograft mouse models.
Physicochemical Properties
M.Wt
433.72
Formula
C7H2N2Br4
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
4,5,6,7-Tetrabromo-1H-benzimidazole
References
1. Zień P, et al. Biochem Biophys Res Commun. 2003 Jun 20;306(1):129-33.
2. Zien P, et al. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):271-80.
3. Nitta RT, et al. Oncogene. 2015 Jul;34(28):3688-99.
